New Delhi, Jul 5 (PTI) Biocon Biologics on Wednesday said it has completed the integration of the acquired biosimilars business from Viatris Inc in over 70 countries in emerging markets effective July 1, 2023, increasing the scale and scope of its business.

Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics, the company said in a statement.

Also Read | Maharashtra Rain Forecast: Officials Issue Red Alert of Excessive Rainfall in Raigad District.

A robust integration plan has ensured a seamless transition of partners, people, systems, and processes across these countries, it added.

Biocon Biologics is a subsidiary of Biocon Ltd.

Also Read | Shooting During US Independence Day 2023 Celebrations: 9 People Shot and Wounded in Washington DC While Enjoying Fourth of July Holiday.

"The successful integration of Viatris' biosimilars business to Biocon Biologics in over 70 countries is a significant milestone and marks the beginning of the transition process," Biocon Biologics CEO & Managing Director Shreehas Tambe said in a statement.

Working closely with partners, Biocon Biologics will now lead commercial operations in these markets and broaden access to patients with a differentiated portfolio of biosimilars, he added.

In February last year, Biocon Biologics inked a pact to acquire Viatris Inc's biosimilars business for consideration of up to USD 3.33 billion.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)